Platelet-targeting approach offers a new path to safer thrombosis protection
Glycoprotein VI, or GPVI for short, is a surface receptor found exclusively on platelets and their precursor cells, megakaryocytes in the bone marrow. GPVI is primarily responsible for binding collagen at the site of an injured blood vessel, which triggers the activation and aggregation of platelets.
Glycoprotein VI, or GPVI, is a surface receptor on platelets and megakaryocytes that is crucial for stopping bleeding by binding collagen at injury sites. However, overactive GPVI can lead to dangerous blood clots, causing heart attacks or strokes. Dr. Bernhard Nieswandt discovered GPVI's role in 2001 and has since been developing GPVI inhibitors to protect against thrombosis.
Boehringer Ingelheim and EMFRET Analytics have partnered to license GPVI-blocking antibody EMA601, which was shown to effectively prevent thrombosis without harming normal clotting. Researchers have now discovered a new method to reduce GPVI's density on platelets by half using low-affinity antibodies called JAQ1 antibodies. This "GPVILO" condition maintains hemostasis, prevents thrombosis, and reduces prothrombotic signaling, while remaining safe even when combined with high-dose aspirin.
This novel approach could lead to safer drugs for preventing thrombosis and treating inflammatory diseases.
Written by urgent.news from Medical Xpress's reporting — not their text. Machine-written — may contain errors; check the original before relying on it.
